Nat Commun:探索癌症治疗新思路,构建癌症eRNA表达图谱并揭示其在癌症临床中的应用

2019-10-13 酶美 BioArt

增强子(enhancer)是一类具有调控功能的远端DNA序列,转录自增强子区域的非编码RNA被称为enhancerRNA(eRNA)。迄今为止,在人类不同组织和器官中已检测到数以千计的eRNA。eRNA在基因的表达调控中起着重要的作用:作为增强子激活的标记;作为转录因子复合物的成分参与录调控的过程中。因此,eRNA在疾病的发展与诊疗中备受青睐。然而,eRNA在癌症发生中的表达图谱及应用仍不明朗。

增强子(enhancer)是一类具有调控功能的远端DNA序列,转录自增强子区域的非编码RNA被称为enhancerRNA(eRNA)。迄今为止,在人类不同组织和器官中已检测到数以千计的eRNA。eRNA在基因的表达调控中起着重要的作用:作为增强子激活的标记;作为转录因子复合物的成分参与录调控的过程中。因此,eRNA在疾病的发展与诊疗中备受青睐。然而,eRNA在癌症发生中的表达图谱及应用仍不明朗。

德克萨斯大学休斯敦健康研究中心的韩冷、李文博课题组合作在Nature Communications上在线发表题为“Transcriptionallandscape and clinical utility of enhancer RNAs for eRNA-targeted therapy incancer”的研究。该研究构建了迄今为止最完整的癌症eRNA图谱并揭示了eRNA在癌症临床中的潜在应用。

该项研究通过检测eRNA在约1万名癌症病人(美国癌症基因图谱计划,TheCancer Genome Atlas,TCGA)及约1000个癌症细胞系(癌细胞系百科全书,CancerCell Line Encyclopedia,CCLE)中的表达构建了目前为止最全面的癌症eRNA图谱,揭示了eRNA的癌症特异性表达/癌症种系特异性表达的特征(图1),同时强调了eRNA作为生物标记物在不同类型癌症临床上的应用。通过研究eRNA与转录因子之间的共表达关系,发现eRNA的特异性表达与转录因子特异性调控密切相关。通过分析eRNA与编码基因之间的基因组距离及表达相关性并结合多组Hi-C数据加以佐证,该研究构建了eRNA的调控网络,揭示了eRNA在调控致癌信号通路及调节癌症临床治疗基因中的关键作用。此外,该研究通过调查eRNA与抗癌化合物(癌症治疗反应数据库,CancerTherapeutics Response Portal ,CTRP;癌症基因组学药物敏感数据库,Genomicsof Drug Sensitivity in Cancer,GDSC)之间的关系,首次证实eRNA可影响癌症细胞对抗癌药物的敏感性和抵抗性,且该影响可能会关联到相关的一条或多条癌症信号通路。

该研究进一步证实致癌基因NET1相关的eRNA,NET1e,具有促进乳腺癌增殖的作用。特异性靶向NET1e可以降低乳腺癌细胞的增殖速度并改善抗癌药物BEZ235及Obatoclax的敏感度。该研究建立了首个eRNA数据库(eRic,https://hanlab.uth.edu/eRic/),包含了eRNA表达、调控、临床相关性及药物敏感性的各种信息,以方便读者查阅。

这项研究拓展了该领域对癌症基因转录调控的认知,探索了基于靶向eRNA的癌症治疗及联合治疗方案,开拓了癌症治疗新思路。

据悉,张朝、Joo-Hyung Lee和阮航博士为该论文的共同第一作者,韩冷和李文博教授为本文的共同通讯。韩冷教授研究组(实验室网站https://med.uth.edu/bmb/labs/han/labnews/)长期致力于利用生物大数据研究癌症等复杂疾病的致病机理。

其研究团队利用TCGA等大规模数据深入研究了癌症的发生机制和药物反应,以通讯作者身份在Nature Metabolism, Nature Immunology, Nature Commutations,Journal of the National Cancer Institute, Trends in Cancer, Cell Systems, Cell Reports等杂志发表多篇论文,被引用超过8000次。现有博士研究生及博士后职位空缺,欢迎感兴趣的同学加盟(leng.han@uth.tmc.edu)。

李文博教授课题组主要关注非编码RNA在染色体水平上对基因表达的调控,以及对染色体三维高级结构的作用。同时也关注非编码RNA在癌症和其他疾病中的异常变化导致的病态表型。

原始出处:
Zhang Z1, Lee JH1, Ruan H1,et al.Transcriptional landscape and clinical utility of enhancer RNAs for eRNA-targeted therapy in cancer.Nat Commun. 2019 Oct 8;10(1):4562. doi: 10.1038/s41467-019-12543-5.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2008752, encodeId=d9f62008e525e, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Tue Dec 10 17:11:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883918, encodeId=89801883918a7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Aug 23 18:11:00 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793446, encodeId=78b81e9344672, content=<a href='/topic/show?id=d96c155e526' target=_blank style='color:#2F92EE;'>#RNA表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15575, encryptionId=d96c155e526, topicName=RNA表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72bf2500198, createdName=小小小向日葵, createdTime=Sun Mar 01 09:11:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785766, encodeId=bd641e857663e, content=<a href='/topic/show?id=7c5c695574' target=_blank style='color:#2F92EE;'>#eRNA表达图谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6955, encryptionId=7c5c695574, topicName=eRNA表达图谱)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Nov 19 16:11:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087607, encodeId=bedc208e607c4, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Aug 05 23:11:00 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019358, encodeId=a2c12019358d1, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Mon Apr 27 15:11:00 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844293, encodeId=192e184429376, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Mar 08 18:11:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]
    2019-12-10 般若傻瓜
  2. [GetPortalCommentsPageByObjectIdResponse(id=2008752, encodeId=d9f62008e525e, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Tue Dec 10 17:11:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883918, encodeId=89801883918a7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Aug 23 18:11:00 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793446, encodeId=78b81e9344672, content=<a href='/topic/show?id=d96c155e526' target=_blank style='color:#2F92EE;'>#RNA表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15575, encryptionId=d96c155e526, topicName=RNA表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72bf2500198, createdName=小小小向日葵, createdTime=Sun Mar 01 09:11:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785766, encodeId=bd641e857663e, content=<a href='/topic/show?id=7c5c695574' target=_blank style='color:#2F92EE;'>#eRNA表达图谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6955, encryptionId=7c5c695574, topicName=eRNA表达图谱)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Nov 19 16:11:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087607, encodeId=bedc208e607c4, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Aug 05 23:11:00 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019358, encodeId=a2c12019358d1, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Mon Apr 27 15:11:00 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844293, encodeId=192e184429376, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Mar 08 18:11:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]
    2020-08-23 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=2008752, encodeId=d9f62008e525e, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Tue Dec 10 17:11:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883918, encodeId=89801883918a7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Aug 23 18:11:00 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793446, encodeId=78b81e9344672, content=<a href='/topic/show?id=d96c155e526' target=_blank style='color:#2F92EE;'>#RNA表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15575, encryptionId=d96c155e526, topicName=RNA表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72bf2500198, createdName=小小小向日葵, createdTime=Sun Mar 01 09:11:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785766, encodeId=bd641e857663e, content=<a href='/topic/show?id=7c5c695574' target=_blank style='color:#2F92EE;'>#eRNA表达图谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6955, encryptionId=7c5c695574, topicName=eRNA表达图谱)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Nov 19 16:11:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087607, encodeId=bedc208e607c4, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Aug 05 23:11:00 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019358, encodeId=a2c12019358d1, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Mon Apr 27 15:11:00 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844293, encodeId=192e184429376, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Mar 08 18:11:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2008752, encodeId=d9f62008e525e, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Tue Dec 10 17:11:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883918, encodeId=89801883918a7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Aug 23 18:11:00 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793446, encodeId=78b81e9344672, content=<a href='/topic/show?id=d96c155e526' target=_blank style='color:#2F92EE;'>#RNA表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15575, encryptionId=d96c155e526, topicName=RNA表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72bf2500198, createdName=小小小向日葵, createdTime=Sun Mar 01 09:11:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785766, encodeId=bd641e857663e, content=<a href='/topic/show?id=7c5c695574' target=_blank style='color:#2F92EE;'>#eRNA表达图谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6955, encryptionId=7c5c695574, topicName=eRNA表达图谱)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Nov 19 16:11:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087607, encodeId=bedc208e607c4, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Aug 05 23:11:00 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019358, encodeId=a2c12019358d1, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Mon Apr 27 15:11:00 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844293, encodeId=192e184429376, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Mar 08 18:11:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2008752, encodeId=d9f62008e525e, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Tue Dec 10 17:11:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883918, encodeId=89801883918a7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Aug 23 18:11:00 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793446, encodeId=78b81e9344672, content=<a href='/topic/show?id=d96c155e526' target=_blank style='color:#2F92EE;'>#RNA表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15575, encryptionId=d96c155e526, topicName=RNA表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72bf2500198, createdName=小小小向日葵, createdTime=Sun Mar 01 09:11:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785766, encodeId=bd641e857663e, content=<a href='/topic/show?id=7c5c695574' target=_blank style='color:#2F92EE;'>#eRNA表达图谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6955, encryptionId=7c5c695574, topicName=eRNA表达图谱)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Nov 19 16:11:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087607, encodeId=bedc208e607c4, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Aug 05 23:11:00 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019358, encodeId=a2c12019358d1, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Mon Apr 27 15:11:00 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844293, encodeId=192e184429376, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Mar 08 18:11:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]
    2020-08-05 liuli5079
  6. [GetPortalCommentsPageByObjectIdResponse(id=2008752, encodeId=d9f62008e525e, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Tue Dec 10 17:11:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883918, encodeId=89801883918a7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Aug 23 18:11:00 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793446, encodeId=78b81e9344672, content=<a href='/topic/show?id=d96c155e526' target=_blank style='color:#2F92EE;'>#RNA表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15575, encryptionId=d96c155e526, topicName=RNA表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72bf2500198, createdName=小小小向日葵, createdTime=Sun Mar 01 09:11:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785766, encodeId=bd641e857663e, content=<a href='/topic/show?id=7c5c695574' target=_blank style='color:#2F92EE;'>#eRNA表达图谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6955, encryptionId=7c5c695574, topicName=eRNA表达图谱)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Nov 19 16:11:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087607, encodeId=bedc208e607c4, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Aug 05 23:11:00 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019358, encodeId=a2c12019358d1, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Mon Apr 27 15:11:00 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844293, encodeId=192e184429376, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Mar 08 18:11:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]
    2020-04-27 晓辰
  7. [GetPortalCommentsPageByObjectIdResponse(id=2008752, encodeId=d9f62008e525e, content=<a href='/topic/show?id=db6969548d' target=_blank style='color:#2F92EE;'>#eRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6954, encryptionId=db6969548d, topicName=eRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Tue Dec 10 17:11:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883918, encodeId=89801883918a7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Aug 23 18:11:00 CST 2020, time=2020-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793446, encodeId=78b81e9344672, content=<a href='/topic/show?id=d96c155e526' target=_blank style='color:#2F92EE;'>#RNA表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15575, encryptionId=d96c155e526, topicName=RNA表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72bf2500198, createdName=小小小向日葵, createdTime=Sun Mar 01 09:11:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785766, encodeId=bd641e857663e, content=<a href='/topic/show?id=7c5c695574' target=_blank style='color:#2F92EE;'>#eRNA表达图谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6955, encryptionId=7c5c695574, topicName=eRNA表达图谱)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Nov 19 16:11:00 CST 2019, time=2019-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087607, encodeId=bedc208e607c4, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Aug 05 23:11:00 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019358, encodeId=a2c12019358d1, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Mon Apr 27 15:11:00 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844293, encodeId=192e184429376, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Sun Mar 08 18:11:00 CST 2020, time=2020-03-08, status=1, ipAttribution=)]

相关资讯

Nat Med:“1/3癌症患者是被吓死的”,精神压力大竟然导致癌症治疗失败?

癌症是一种高度异质性的疾病。由于恶性肿瘤细胞以及肿瘤微环境的独特性,不同癌症患者的疾病状态并不相同。可以说,“***千面”是癌症难以治疗的重要原因之一。人们付出了大量的时间与精力,致力于发现内在固有的本质,实现癌症治愈。

Lancet Public Health:促进癌症早发现的10大研究重点

近日,柳叶刀子刊《The Lancet Public Health》刊登了一篇文章,提出了癌症早期诊断的十大研究重点,关注癌症研究进展的你,不要错过这篇文章!

ESMO复盘,这些重磅研究你都知道吗?

本周,在西班牙巴塞罗那举行的ESMO大会落下了帷幕。有些分析师指出,与今年相对“略显平静”的ASCO年会相比,ESMO大会可谓“火热”异常。多款创新疗法在癌症治疗领域拿到了“首个”突破性进展。今天,药明康德内容团队将与各位读者朋友们复盘今年ESMO大会上的一些亮点。

Nature:癌症患者或能从“超适应症”药物中获益

《自然》发表的一项研究The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs显示,某些癌症患者或能从“超适应症”(off-label)药物中获益,即这类药物在常规情况下不会用于他们所患类型的肿瘤治疗中。这项研究是前瞻性试验“药物再发现”(Drug Rediscovery Prot

PDE5抑制剂或可用于血液癌症治疗 单次口服媲美Neupogen注射4天

造血干细胞移植在血液癌症治疗中可以挽救患者的生命,但高效地收集干细胞用于移植仍存在障碍。来自美国加州大学圣克鲁斯分校(UCSC)一个研究团队的最新研究证据表明,辉瑞的勃起功能障碍(ED)治疗药物伟哥可有效促进造血干细胞从骨髓释放至血液中,从而使获取造血干细胞更容易。

CAR-T治疗实体瘤设计策略解析

免疫蛋白质组学发现肿瘤相关抗原(TAAs)。这些抗原可能是完全未知的蛋白质(新抗原)或从野生型突变的肽(新表位)。利用蛋白质组学鉴定的TAAs的几个例子包括PSMA1、PAP3、ANXA3和MASPIN,这几个标记被一组鉴定为结肠癌的生物标志物。其他具有潜在靶向性的TAAS包括olfactomedin4、CD11b和整合素α-2,它们在结直肠癌肝转移中被发现过度表达。